Yuichi Yomasu, president of Daiichi Sankyo China, shares his first impressions of the dynamic but complex Chinese market since he assumed position ten months ago; the strategic importance of the Chinese affiliate to the Group’s overall business, particularly in light of the Group’s transition towards an innovative leader in oncology by 2025; and his dream to take Daiichi Sankyo China to the next level in the next few years.
Recent reforms have made it clear that oncology is a national priority for the Chinese government
